Edward Lee Carter: Are All DOACs Truly Interchangeable in Real-World Practice?
Edward Lee Carter, Clinical Pharmacist Practitioner at U.S. Department of Veterans Affairs, shared a post on LinkedIn:
”Apixaban vs Rivaroxaban — are we starting to see separation?
The COBBRA trial (March 2026) adds another important data point to a question many of us deal with daily:
Are all DOACs truly interchangeable in real-world practice?
COBBRA compared Apixaban vs Rivaroxaban in a contemporary patient population, focusing on both effectiveness and bleeding risk.
Key takeaway (high-level):
Apixaban demonstrated a more favorable bleeding profile, while maintaining comparable effectiveness for thromboembolic prevention.
That signal is not entirely new—but it’s becoming more consistent.
Why this matters in practice:
We often think of DOACs as a class.
But clinically, they behave more like related—but distinct—tools.
What COBBRA reinforces:
- Bleeding risk is not uniform across DOACs
- Patient selection still matters (renal function, age, weight, comorbidities)
- ‘One-size-fits-all anticoagulation’ continues to fall short
Practical considerations:
Apixaban
- Lower observed bleeding rates in multiple datasets
- BID dosing (may improve peak/trough stability)
Rivaroxaban
- Once-daily dosing (adherence advantage for some patients)
- Still a strong, guideline-supported option
The bigger picture:
We’re seeing convergence from:
- RCTs
- Real-world data
- Now additional comparative trials like COBBRA
And the trend is fairly consistent:
- Apixaban often emerges with a bleeding advantage
- Effectiveness remains comparable
For clinicians:
This isn’t about declaring a ‘winner.’
It’s about refining decisions at the bedside.
Matching the right anticoagulant to the right patient
Balancing bleeding risk vs adherence vs comorbidity profile
Bottom line:
DOACs may share a mechanism – but they do not share identical clinical outcomes.”
Stay updated with Hemostasis Today.
-
Nov 8, 2026, 18:28Raghavendra Rao: A Narrative Review on Chronic Venous Disease during Pregnancy
-
Nov 8, 2026, 17:57Dhiren Patel: PLD1-Derived Phospholipids Regulate NAD Kinase and ROS Production in Neutrophils
-
Nov 8, 2026, 17:48Andra T.: What Causes Antiphospholipid Syndrome? – Four Steps, not One Cause
-
Nov 8, 2026, 17:38Nasrin Samadi: Can a Normal Clotting Test Be Misleading?
-
Nov 8, 2026, 17:36Paschalis Evangelidis: The Multifactorial Nature of Cardiovascular Risk in People With Hemophilia
-
Nov 8, 2026, 17:32Evangelos Panagiotopoulos: Apixaban Reduces Stroke and Major Bleeding Risk in Secondary Stroke Prevention
-
Nov 8, 2026, 17:27Danny Gaskin: Applications Open for the BBTS Specialist Certificate in Clinical Transfusion Practice
-
Nov 8, 2026, 16:54James P. Crowley: DOAC Testing Under 50 ng/mL Safely Expedites Urgent Hip Fracture Surgery
-
Nov 8, 2026, 16:21Alessandra Bosch: Women and Girls With Bleeding Disorders and the DACH Registries at HHS 2026